Overview

Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations

Status:
Completed

Trial end date:
2019-07-02

Target enrollment:

Participant gender:

Summary

Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.

Phase:

Phase 4

Details

Lead Sponsor:

McGill University Health Center
McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborators:

CIHR Canadian HIV Trials Network
ViiV Healthcare

Treatments:

Abacavir
Dolutegravir
Lamivudine
Triumeq